about
A 69-year-old female with tiredness and a persistent tan.Thyrotoxicosis and pregnancy.Evaluation of an on-call diabetes service in a large teaching hospital.Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases.A 52-year-old female with a hoarse voice and tingling in the handConsensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment.Phaeochromocytomas presenting as acute crises after beta blockade therapy.Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility.Patient knowledge of antithyroid drug-induced agranulocytosisOrbital decompression for Graves' orbitopathy in EnglandMilk alkali syndrome without the milkSerum thyrotropin is a better predictor of future thyroid dysfunction than thyroid autoantibody status in biochemically euthyroid patients with diabetes: implications for screening.Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey.rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers.Anti-mitochondrial antibodies in patients with Graves' disease may not signify primary biliary cirrhosis.The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' OrbitopathyPsychological implications of Graves' orbitopathy.SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis.Thyroid-associated orbitopathy: who and how to treat.Graves orbitopathy: a perspective.Management plan and delivery of care in Graves' ophthalmopathy patients.The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines.Thyroglobulin in differentiated thyroid cancer.Diagnosis of Graves' orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologists.Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee.Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.Thyroid-associated ophthalmopathy: pathogenesis and clinical management.PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.Fatal inflammatory hypophysitis.Further evidence for a susceptibility locus on chromosome 20q13.11 in families with dominant transmission of Graves disease.Rising serum 25-hydroxy-vitamin D levels after weight loss in obese women correlate with improvement in insulin resistance.Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement.Cushing's syndrome without excess cortisol.The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey.Management of a pregnant patient with Graves' disease complicated by thionamide-induced neutropenia in the first trimester.Multiple endocrine neoplasia type 2A: an unusual clinical presentation and association with renal dysplasia.Saving lives of in-patients with adrenal insufficiency: implementation of an alert scheme within the Newcastle-upon-Tyne Hospitals e-Prescribing platform.
P50
Q24816916-312D1A0F-324C-47FD-94BB-3A6918087AE7Q25255514-18B33850-D371-4080-9819-E2F309B65B0CQ30482084-20FB8A4A-CC3F-42B7-BC81-8DE505FAAC34Q33218730-68470C41-DBD3-48AC-AADD-A97258973615Q33277098-966DCF42-EFB6-4ED3-B2C4-EF276D4002EAQ34010116-DCA9E98E-D4D4-45E3-A90C-95EAC27338B6Q34394088-783C7060-F3C4-4298-9A49-F2B682EC2746Q34569618-C26DD238-C4DF-41AE-A19B-19F2251D239FQ34632596-9A1BB963-E9AE-42EC-AD12-2A28FDDBFB38Q35029667-8B9936C7-DD64-4BF3-8272-C051F17E9DBEQ35820372-9ADD1239-E817-4847-8AC6-F2A5E24066D4Q35951165-777624C2-8852-4B26-8666-FE9C744053D4Q35978553-D23D5298-3239-4272-BF99-F1A75BFDB6CDQ36014781-A9B1CF65-76A2-4EE3-9D08-DDA1D72517CFQ36078981-B8DA2DF8-1549-4F26-A32C-94268F208878Q36568033-7F3F3982-0CCE-4AF7-BEE8-14BD8162BB66Q36678839-F576D27B-BAD8-4825-84A5-043DA66C962AQ36811289-E04ADCB7-0EE2-473D-A4BC-0EF945F75FB4Q36893372-6540F4E1-5FEE-4353-B144-5B1B7D287ED4Q37382179-5C937F99-AD93-44A9-BF77-DF7783071AF0Q37425768-38532E95-1AF8-422C-A31C-F8EDB2656A4CQ37472924-CC7E0FB2-E47C-4EBD-8DB1-BAE9C4922543Q38013213-F1D5281D-D211-4D44-BB6E-B060A41C6F89Q38232848-BE109EE0-81BC-493A-938E-9F4DC8628FD2Q38274735-799C638C-8A7E-4667-9A96-E36F2C4C936EQ38285063-16794A74-1064-440C-9275-5740350A2CFDQ38502679-092ACD16-9B45-4D4A-8BD1-D0B863947EABQ38692635-A42C085F-8E52-4ED7-85F2-10BEC7805F46Q39176092-7009A50A-C49A-4C71-9CA5-570526982712Q40511567-EFE99A98-47B9-4AB7-A7A5-A55560DE2F61Q40962257-7ED33057-475C-42DA-B43B-F44F0ECCE04CQ42011804-FCF6345F-5B26-4E85-994C-6DD2DF1FF703Q42698446-B8057A32-1630-43B4-BF27-6A1EB1D6BCFFQ43037163-98F25359-1455-4FDC-A8AA-FB1A6B1061BFQ43165236-BAF5E2F6-4220-4588-BBAA-C6E24C1CAD14Q43225530-C36A3657-1D16-4CED-BC30-FFEE97012528Q43579038-A1CF48AC-15D1-49CD-9399-7D0848291920Q43586033-41ED79BF-2AD2-452E-A898-E45230CA9204Q44328507-EEB16350-37DF-40EB-A22F-1CDDF814BAF2Q44821508-7EBCCEAD-3C46-4905-9B9C-90A05538D744
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Petros Perros
@ast
Petros Perros
@en
Petros Perros
@es
Petros Perros
@nl
Petros Perros
@sl
type
label
Petros Perros
@ast
Petros Perros
@en
Petros Perros
@es
Petros Perros
@nl
Petros Perros
@sl
prefLabel
Petros Perros
@ast
Petros Perros
@en
Petros Perros
@es
Petros Perros
@nl
Petros Perros
@sl
P106
P1153
7006707944
P21
P31
P496
0000-0001-7320-5574